阳光诺和ABA001注射液临床试验申请获得受理

Core Viewpoint - Sunshine Nuohuo (688621) announced that it has received the acceptance notice from the National Medical Products Administration for its clinical trial application of the innovative drug ABA001 injection, which is intended for the treatment of hypertension [1]. Company Summary - Sunshine Nuohuo and its wholly-owned subsidiary, Beijing Arna Technology Co., Ltd., have submitted a clinical trial application for ABA001 injection, classified as a Class 1 innovative drug [1]. - The proposed indication for ABA001 injection is hypertension, indicating the company's focus on addressing significant health issues [1].